| Management |
| Jean-Patrick Voisin, MBA Chairman & C.E.O. |
| Luc Lenglet, ENS Senior Vice President, R&D |
| Petr Nikitin, PhD Chief Scientific Officer |
| Advisors |
| Dominique Bellet, PharmD, MD, PhD |
| Jean-Claude Mongrenier, PharmD, MBA |
| Christian Policard, Docteur in Biochemistry |
| Bernard Pau, PhD |
| Partners |
| Russian Academy of Sciences |
| University of Paris 13 |
| Bertin Technologies |
University of Paris 13
The Paris 13 University is one of the thirteen universities wich have succeeded La Sorbonne in 1968. Currently nearly 22000 students and more than 1400 permanents are working at the UP13. It is the biggest multi-discipline university in France. The Bionanomaterials activity , FRE CNRS 3043 (C2B team), directed by Pr. Laurence Motte since Sept. 2005, is dedicated to the elaboration and characterization of magnetic nanobiovectors for molecules vectorization, for diagnostic and/or therapeutic applications. |
History - Milestones
2006: Creation of Magnisense SARL in Luxembourg.
2007: Creation of Magnisense France SARL.
2008: Creation of Magnisense Labs at Dardilly, France.
2009: Magnisense's princeps patent is issued in Europe.
2010: Magnisense's princeps patent is issued in the United States.
2010: Transfert of Magnisense SE from Luxembourg to France.
2011: Merger of Magnisense France SARL into Magnisense SE in France.